ALNOX.PA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...

Stats
Dagens volum	10.21M
Gjennomsnittsvolum	4.35M
Markedsverdi	0.00
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.187
ATR14	€0 (0.00%)

NOXXON Pharma NV Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

NOXXON Pharma NV Økonomi

Annual	2021
Omsetning:	€0.00
Bruttogevinst:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2021
Omsetning:	€0.00
Bruttogevinst:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2020
Omsetning:	€0.00
Bruttogevinst:	€0.00 (0.00 %)
EPS:	€-32.16

FY	2019
Omsetning:	€0.00
Bruttogevinst:	€-1.03M (0.00 %)
EPS:	€-7.72

Financial Reports:

No articles found.

NOXXON Pharma NV

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.